Clinical Trial Update: A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function. [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics study evaluating Sativex in subjects with severe renal impairment or end-stage renal disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Sativex (nabiximol)

Snippet

Sponsor: GW Pharmaceuticals Ltd | Conditions: Renal Insufficiency, Kidney Disease | Phase 1 | Status: WITHDRAWN